Biovance Capital Partners Launches with €51M to Boost Biotech in Southern Europe

1. Launch and Funding: Biovance Capital Partners, a new venture capital company, has launched with €51 million to invest in early-stage biotech companies in Southern Europe.
2. Focus: The fund will focus on Seed and Series A rounds, investing in companies developing novel therapies for unmet medical needs across all disease areas and drug modalities.
3. Management: The fund will be managed by a team of healthcare-specialized PhDs and an MD with track records in the pharmaceutical and venture capital industries.
4. Investors: The fund has secured commitments from the European Investment Fund (EIF), the European Commission, Banco Português de Fomento (BPF), Caixa Capital, and institutional investors in the U.S. and Portugal.
5. Objective: The fund aims to create more biotech companies in Portugal and the rest of Europe, capturing value from the highly profitable and largely untapped market opportunity.